BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20592016)

  • 1. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
    Bednarz N; Eltze E; Semjonow A; Rink M; Andreas A; Mulder L; Hannemann J; Fisch M; Pantel K; Weier HU; Bielawski KP; Brandt B
    Clin Cancer Res; 2010 Jul; 16(13):3340-8. PubMed ID: 20592016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
    Omari A; Nastały P; Stoupiec S; Bałabas A; Dąbrowska M; Bielińska B; Huss S; Pantel K; Semjonow A; Eltze E; Brandt B; Bednarz-Knoll N
    Int J Cancer; 2019 Feb; 144(3):607-614. PubMed ID: 30265376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
    Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
    J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
    Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
    Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic imbalance in the clonal evolution of prostate carcinoma.
    Cheng L; Bostwick DG; Li G; Wang Q; Hu N; Vortmeyer AO; Zhuang Z
    Cancer; 1999 May; 85(9):2017-22. PubMed ID: 10223244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
    Schwarzenbach H; Alix-Panabières C; Müller I; Letang N; Vendrell JP; Rebillard X; Pantel K
    Clin Cancer Res; 2009 Feb; 15(3):1032-8. PubMed ID: 19188176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
    Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
    Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
    Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
    [No Abstract]   [Full Text] [Related]  

  • 13. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
    Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
    Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression.
    Takahashi S; Shan AL; Ritland SR; Delacey KA; Bostwick DG; Lieber MM; Thibodeau SN; Jenkins RB
    Cancer Res; 1995 Sep; 55(18):4114-9. PubMed ID: 7664288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic loss in locally metastatic, multisampled prostate cancer.
    Sakr WA; Macoska JA; Benson P; Grignon DJ; Wolman SR; Pontes JE; Crissman JD
    Cancer Res; 1994 Jun; 54(12):3273-7. PubMed ID: 7515768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma.
    Murray SK; Breau RH; Guha AK; Gupta R
    Am J Surg Pathol; 2004 Sep; 28(9):1154-62. PubMed ID: 15316314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer.
    Kothari PS; Scardino PT; Ohori M; Kattan MW; Wheeler TM
    Am J Surg Pathol; 2001 Nov; 25(11):1429-32. PubMed ID: 11684961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.